Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1949 1
1950 4
1951 1
1953 3
1954 1
1955 1
1956 2
1958 2
1959 1
1960 2
1962 1
1963 3
1964 1
1965 5
1966 4
1967 3
1968 1
1970 2
1971 2
1972 1
1974 1
1975 1
1976 2
1977 1
1978 2
1979 3
1980 3
1981 7
1982 6
1983 7
1984 3
1985 6
1986 7
1987 3
1988 3
1989 6
1992 1
1993 1
1994 3
1995 6
1996 4
1997 4
1998 5
1999 1
2000 2
2001 7
2002 2
2003 3
2005 1
2006 5
2007 4
2008 2
2009 6
2010 7
2011 7
2012 4
2013 11
2014 8
2015 7
2016 3
2017 5
2018 4
2019 3
2020 1
2021 4
2022 3
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Long GV, et al. Among authors: blaustein a. Ann Oncol. 2024 Dec;35(12):1191-1199. doi: 10.1016/j.annonc.2024.08.2330. Epub 2024 Sep 15. Ann Oncol. 2024. PMID: 39306585 Free article. Clinical Trial.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Robert C, et al. Among authors: blaustein a. J Clin Oncol. 2023 Aug 20;41(24):3998-4003. doi: 10.1200/JCO.22.01599. Epub 2023 Jun 22. J Clin Oncol. 2023. PMID: 37348035
Optimal medical therapy with or without PCI for stable coronary disease.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Boden WE, et al. Among authors: blaustein as. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26. N Engl J Med. 2007. PMID: 17387127 Free article. Clinical Trial.
ARTHROGRAPHY.
Blaustein A. Blaustein A. Can Med Assoc J. 1946 May;54(5):491-2. Can Med Assoc J. 1946. PMID: 20323786 Free PMC article. No abstract available.
Explaining frog deformities.
Blaustein AR, Johnson PT. Blaustein AR, et al. Sci Am. 2003 Feb;288(2):60-5. doi: 10.1038/scientificamerican0203-60. Sci Am. 2003. PMID: 12561459 No abstract available.
223 results